Why Promotion Can Outpace Discovery
A medicine does not become a major seller simply because it works. Doctors must know it is available, understand which patients it may suit, and decide how it compares with alternatives. Companies compete for that attention through sales representatives, professional meetings, educational materials, free samples, and advertising to consumers where permitted. These activities can reach many people quickly; developing a new medicine requires years of research and testing, with no guarantee that a candidate will succeed.
That difference creates a business incentive. Research is an investment in a product that may never reach the market. Promotion is aimed at medicines already approved for sale, where persuading more prescribers or patients to choose one brand over another can affect revenue during the period it has market protection. The two budgets therefore serve different purposes: one tries to create a future product, while the other tries to build demand for products the company can sell now.
What the Spending Tradeoff Means
Promotion is not automatically wasteful: doctors need reliable information about new treatments, and patients may benefit from learning about available options. But promotional messages are designed to increase use of a company’s products, not to provide a neutral comparison of every treatment. That makes independent clinical guidance and evidence important alongside company materials.
The distinction also helps explain why a firm’s spending priorities may not match the public’s hopes. A company can gain more immediate financial benefit from winning prescriptions for an existing drug than from funding research whose outcome—and commercial value—remains uncertain. The result is a tension between discovering better medicines and persuading the market to choose the ones already on the shelf.
